Simplex Trading
FDMT icon

Simplex Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Simplex Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,660
Closed -$211K – 9582
2026
Q1 		$202K Buy
+21,660
New +$189K ﹤0.01% 4285
2025
Q4 		– Sell
-2,925
Closed -$25K – 8995
2025
Q3 		$25K Sell
2,925
-6,436
-69% -$38.5K ﹤0.01% 7130
2025
Q2 		$34K Buy
9,361
+5,048
+117% +$17.7K ﹤0.01% 6287
2025
Q1 		$13K Sell
4,313
-10,418
-71% -$49.1K ﹤0.01% 6901
2024
Q4 		$82K Buy
+14,731
New +$116K ﹤0.01% 5361
2024
Q2 		– Sell
-4,741
Closed -$119K – 9067
2024
Q1 		$151K Sell
4,741
-6,369
-57% -$162K ﹤0.01% 5147
2023
Q4 		$225K Buy
11,110
+10,844
+4,077% +$143K ﹤0.01% 4548
2023
Q3 		$3K Buy
+266
New +$4.45K ﹤0.01% 7885
2022
Q3 		– Sell
-602
Closed -$5.45K – 10182
2022
Q2 		$4K Buy
+602
New +$5.85K ﹤0.01% 8956

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Simplex Trading's FDMT Position: Q2 2026 in Review

Simplex Trading sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 21,660 shares — an estimated $211K sold.

Simplex Trading first reported a position in FDMT in Q2 2022 and held it in 9 quarters. The position peaked at $225K in Q4 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Simplex Trading reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 21,660 4D Molecular Therapeutics shares in Q2 2026, an estimated $211K.
  • Simplex Trading first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 9 quarters.
  • Simplex Trading's 4D Molecular Therapeutics position peaked at $225K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.